RNXT

RenovoRx, Inc.

1.57 USD
+0.26 (+19.85%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

RenovoRx, Inc. stock is up 29.75% since 30 days ago. The next earnings date is Mar 12, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 100% of the previous 2 February’s closed higher than January. 100% of analysts rate it a buy.

About RenovoRx, Inc.

RenovoRx, Inc. focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath.

  • Alliance Global Partners
    Fri Feb 2, 08:02
    buy
    initial